08.05.2023 - Updated interim results from CPI-818 Phase 1/1b clinical trial continues to support potential of ITK inhibition and the ALC biomarker in T cell lymphoma Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., May 08, 2023 (GLOBE .
Equities research analysts expect that Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS – Get Rating) will report ($0.14) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have issued estimates for Corvus Pharmaceuticals’ earnings. Corvus Pharmaceuticals reported earnings of ($0.34) per share during the same quarter last year, which would indicate a positive year-over-year growth […]